Image by Trygve.u via Flickr
Drs. Scott Kitchen, Zoran Galic, Jerry Zack of the UCLA Broad Stem Cell Research Center and AIDS Institute and their colleagues demonstrated for the first time that human blood stem cells can be engineered into cells that can target and kill HIV-infected cells. The process could potentially be used against a range of chronic viral diseases.
The study, published Dec. 7 in the-peer reviewed online journal PLoS ONE, provides proof-of-principle, a demonstration of feasibility, that human stem cells can be engineered into the equivalent of a genetic vaccine.
“We have demonstrated in this proof-of-principle study that
Image via Wikipedia
Transplanting stem cells from one’s own bone marrow (autologous stem cell transplants) improves the symptoms of muscular sclerosis (MS), and in some cases the neurological disease actually regressed. These are the encouraging results obtained from a small study performed on 21 remittent MS patients by a group from the Northwestern University School of Medicine in Chicago and published in Lancet Neurology. “All of the patients,” said the neurologists, “witnessed an improvement in their conditions three years after the stem cell transplants were performed. Of these, 81pct benefited from visible progress, measured in terms of
Historic Hurd Hall on Johns Hopkins’ East Baltimore campus was filled to capacity on Jan. 13 with students, faculty and staff waiting to hear five scientists—all in the early part of their careers—describe their novel ideas on how to cure metastatic cancer.
The five were finalists, chosen from among 44 entrants, in a competition on creative thinking named for John Rangos Sr., chairman of the Rangos Family Foundation, who funded the awards. Each scientist had 10 minutes to present his or her idea and answer questions from a panel of faculty judges, who would select the winners based on the
Fondazione IRCCS Istituto Nazionale Tumori di Milano
Methods to provide safer stem cell transplants to individuals who are not completely compatible with the donor are being developed. Encouraging results have come from a post-transplant cellular therapy, which strengthens the immune system against viral infections and tumors, developed for the first time at the National Tumor Institute (INT) in Milan. The INT conducted the first phase I-II study in the world, published in ‘Blood’, whose main objective was to assess the use of a low dose radiochemotherapy, followed by low dose post-transplant infusions CD8-depleted donor lymphocytes after
Image via Wikipedia
Promising results from a small study may offer hope for the treatment of multiple sclerosis (MS).
Researchers from the University of California – San Diego report dramatic improvement after treating MS patients with stromal vascular fraction (SVF) stem cells from a patient’s own body fat. They say the SVF therapy can limit the body’s immune system reaction and promote the growth of new myelin – the fatty “insulation” on axons in the brain, which breaks down in patients with MS.
“None of the presently available MS treatments selectively inhibit the immune attack against the nervous system, nor do they